Please login to the form below

Not currently logged in
Email:
Password:

rare disease unit

This page shows the latest rare disease unit news and features for those working in and with pharma, biotech and healthcare.

Sanofi extends growth spurt thanks to Genzyme, Dupixent

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news. Sanofi has put a long run of decline caused by patent losses in its rear view mirror, with rare disease unit Genzyme and ... There was positive news for Sanofi’s new play in rare blood disorders.

Latest news

  • Sanofi gets EU OK for Ablynx flagship drug Cablivi Sanofi gets EU OK for Ablynx flagship drug Cablivi

    The new drug is the first new product to come from Sanofi’s push into rare disease therapies and specifically rare blood disorders, which was also behind its $11.6bn acquisition ... s Genzyme rare disease unit.

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    Pfizer Rare Disease Research Unit. ... Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this

  • Dupixent bounce-back helps stem diabetes declines at Sanofi Dupixent bounce-back helps stem diabetes declines at Sanofi

    Rare disease unit Genzyme had a good quarter, with sales up 6% to 743m, but vaccines business Sanofi Pasteur was under pressure with sales falling almost 16% to 811m due to ... hoping that the 3.9bn takeover of antibody specialist Ablynx and lead rare

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Vaccines for Clostridium difficile and staphylococcal infections and a new-generation Prevnar are making progress, along with rare disease therapies tafamidis for neuropathies and rivipansel for vaso-occlusive crises and tanezumab ... In the last few

  • Sanofi warns of difficult few months as diabetes sales slump Sanofi warns of difficult few months as diabetes sales slump

    The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who ... Revenues were however fairly flat if exchange

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest from PMHub

  • Focus on Rare Diseases

    Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise ... Within this unit, Lucid

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics